Literature DB >> 23731845

Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis.

Sonia Burrel1, David Boutolleau, Georges Azar, Serge Doan, Claire Deback, Isabelle Cochereau, Henri Agut, Eric E Gabison.   

Abstract

Herpes simplex virus type 1 (HSV-1) is a leading cause of corneal blindness. Acyclovir (ACV) constitutes the standard treatment of HSV infections including herpetic keratitis (HK). HSV resistance to ACV is mainly described in immunocompromised patients. We describe two cases of ACV-resistant corneal HSV-1 in immunocompetent individuals with recurrent HK.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Herpetic keratitis; Immunocompetent patient; Phenotypic and genotypic antiviral resistance assay; Resistance to acyclovir

Mesh：

Substances：

Year:  2013        PMID： 23731845     DOI： 10.1016/j.jcv.2013.05.001

Source DB:  PubMed          Journal:  J Clin Virol        ISSN： 1386-6532            Impact factor:   3.168


  9 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

Review 2.  Immune response of T cells during herpes simplex virus type 1 (HSV-1) infection.

Authors:  Jie Zhang; Huan Liu; Bin Wei
Journal:  J Zhejiang Univ Sci B       Date:  2017 Apr.       Impact factor: 3.066

3.  Adenovirus-mediated shRNA interference against HSV-1 replication in vitro.

Authors:  Bo Song; Xinjing Liu; Qingzhi Wang; Rui Zhang; Ting Yang; Zhiqiang Han; Yuming Xu
Journal:  J Neurovirol       Date:  2016-08-26       Impact factor: 2.643

4.  Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases.

Authors:  Natacha Coen; Sophie Duraffour; Kazuhiro Haraguchi; Jan Balzarini; Joost J van den Oord; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

5.  Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient.

Authors:  Dongli Pan; Stephen B Kaye; Mark Hopkins; Ruaidhri Kirwan; Ian J Hart; Donald M Coen
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

6.  Herpes Simplex Virus-1 infection in human primary corneal epithelial cells is blocked by a stapled peptide that targets processive DNA synthesis.

Authors:  Hancheng Guan; Manunya Nuth; Vivian Lee; Chenyan Lin; Claire H Mitchell; Wennan Lu; Richard W Scott; Michael H Parker; John L Kulp; Allen B Reitz; Robert P Ricciardi
Journal:  Ocul Surf       Date:  2020-11-06       Impact factor: 5.033

7.  Silencing herpes simplex virus type 1 capsid protein encoding genes by siRNA: a promising antiviral therapeutic approach.

Authors:  Fujun Jin; Shen Li; Kai Zheng; Cuiqin Zhuo; Kaiqi Ma; Maoyun Chen; Qiaoli Wang; Peizhuo Zhang; Jianglin Fan; Zhe Ren; Yifei Wang
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

8.  A Therapeutic Antiviral Antibody Inhibits the Anterograde Directed Neuron-to-Cell Spread of Herpes Simplex Virus and Protects against Ocular Disease.

Authors:  Dirk Bauer; Mira Alt; Miriam Dirks; Anna Buch; Christiane S Heilingloh; Ulf Dittmer; Bernd Giebel; André Görgens; Vivien Palapys; Maren Kasper; Anna M Eis-Hübinger; Beate Sodeik; Arnd Heiligenhaus; Michael Roggendorf; Adalbert Krawczyk
Journal:  Front Microbiol       Date:  2017-10-31       Impact factor: 5.640

9.  Gold Nanoparticles Crossing Blood-Brain Barrier Prevent HSV-1 Infection and Reduce Herpes Associated Amyloid-βsecretion.

Authors:  Rodriguez-Izquierdo I; Serramia Mj; Gomez R; De La Mata Fj; Bullido Mj; Muñoz-Fernández Ma
Journal:  J Clin Med       Date:  2020-01-07       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.